AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10232418 — intervention group
Group type: EXPERIMENTAL
Intervention: SK+early OP (early surgical drainage with adjunctive intrapleural fibrinolysis)
Number of subjects: 82
Study 10232418 — intervention group
Group type: COMPARATOR
Intervention: Drain (simple chest tube drainage)
Number of subjects: 82
Study 10232418 — intervention group
Group type: COMPARATOR
Intervention: IP-SK (adjunctive intrapleural streptokinase)
Number of subjects: 82
Study 8914031 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor, lisinopril (N = 18)
Number of subjects: 52
Study 8914031 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondihydropyridine calcium channel blockers (NDCCBs), verapamil SR (N = 8) or diltiazem SR (N = 10)
Number of subjects: 52
Study 8914031 — intervention group
Group type: COMPARATOR
Intervention: Beta blocker, atenolol (N = 16)
Number of subjects: 52
Study 1812908 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxyl mouthrinse plus chlorhexidine mouthrinse
Number of subjects: 119
Study 1812908 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse plus chlorhexidine mouthrinse
Number of subjects: 119
Study 6195026 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermovate ointment
Number of subjects: 10
Study 6195026 — intervention group
Group type: COMPARATOR
Intervention: Betnovate ointment (betamethasone valerate 0.1%)
Number of subjects: 10
Study 6195026 — intervention group
Group type: COMPARATOR
Intervention: Propaderm Forte cream (beclomethasone dipropionate 0.5%)
Number of subjects: 10
Study 6195026 — intervention group
Group type: COMPARATOR
Intervention: Propaderm ointment (beclomethasone dipropionate 0.025%)
Number of subjects: 10
Study 6195026 — intervention group
Group type: COMPARATOR
Intervention: Nerisone Forte ointment (diflucortolone valerate 0.3%)
Number of subjects: 10
Study 6195026 — intervention group
Group type: COMPARATOR
Intervention: Nerisone ointment (diflucortolone valerate 0.1%)
Number of subjects: 10
Study 6195026 — intervention group
Group type: COMPARATOR
Intervention: Adcortyl ointment (triamcinolone acetonide 0.1%)
Number of subjects: 10
Study 6195026 — intervention group
Group type: COMPARATOR
Intervention: Ledercort ointment (triamcinolone acetonide 0.1%)
Number of subjects: 10
Study 6195026 — intervention group
Group type: COMPARATOR
Intervention: Extemporaneous dilutions of Adcortyl and Ledercort ointments (triamcinolone acetonide 0.025%)
Number of subjects: 10
Study 31608424 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation training
Number of subjects: 60
Study 31608424 — intervention group
Group type: COMPARATOR
Intervention: Balance training
Number of subjects: 60
Study 31608424 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 60
Study 31428863 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension without tourniquet (group H)
Number of subjects: 122
Study 31428863 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet use (group T)
Number of subjects: 122
Study 28973516 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNECT + FALLS
Number of subjects: 1794
Study 28973516 — intervention group
Group type: COMPARATOR
Intervention: FALLS only
Number of subjects: 1794
Study 27599328 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab nasal spray 25 mg
Number of subjects: 80
Study 27599328 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab nasal spray 50 mg
Number of subjects: 80
Study 27599328 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab nasal spray 75 mg
Number of subjects: 80
Study 27599328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24090228 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 133
Study 24090228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 22973168 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver (Ep)
Number of subjects: 226
Study 22973168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sémont‐Toupet maneuver (ST)
Number of subjects: 226
Study 22973168 — intervention group
Group type: COMPARATOR
Intervention: Postmaneuver restrictions
Number of subjects: 226
Study 19228089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-beam volumetric tomography (CBVT)
Number of subjects: 35
Study 19228089 — intervention group
Group type: COMPARATOR
Intervention: Intraoral radiographs (IRs)
Number of subjects: 35
Study 19228089 — intervention group
Group type: EXPERIMENTAL
Intervention: CBVT
Number of subjects: 35
Study 19228089 — intervention group
Group type: COMPARATOR
Intervention: CBVT and surgical measurements
Number of subjects: 35
Study 17288658 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing assessment by speech-language pathologists (SLPs)
Number of subjects: 24
Study 17288658 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face assessment by speech-language pathologists (SLPs)
Number of subjects: 24
Study 15890740 — intervention group
Group type: COMPARATOR
Intervention: 5000 IU hCG (group A)
Number of subjects: 24
Study 15890740 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg intranasal buserelin followed by 100 microg every 3 days (group B)
Number of subjects: 24
Study 15890740 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg intranasal buserelin followed by 100 microg every 2 days (group C)
Number of subjects: 24
Study 15890740 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg intranasal buserelin followed by 100 microg every day (group D)
Number of subjects: 24
Study 12236274 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based health check with influenza vaccination offer (n = 680, 74.3% uptake)
Number of subjects: 2052
Study 12236274 — intervention group
Group type: COMPARATOR
Intervention: Personal letter invitation to attend vaccination clinic (n = 1,372, 67.9% uptake)
Number of subjects: 2052
Study 9793597 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (1-8 mg once daily)
Number of subjects: 5000
Study 9793597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study 8059694 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 317
Study 8059694 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 317
Study 3381638 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodinated salt (20 mg of iodine as iodate/kg salt consumed, assumed consumption of 5 g salt per day)
Number of subjects: 334
Study 3381638 — intervention group
Group type: COMPARATOR
Intervention: Non-iodinated salt
Number of subjects: 334
Study 3381638 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodinated salt
Number of subjects: 334
Study 29615134 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured debriefings and point-of-care bedside practice emphasizing physiologic resuscitation targets
Number of subjects: 0
Study 29615134 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard CPR training)
Number of subjects: 0
Study 28968232 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio® taping
Number of subjects: 60
Study 28968232 — intervention group
Group type: COMPARATOR
Intervention: Placebo tape
Number of subjects: 60
Study 28968232 — intervention group
Group type: COMPARATOR
Intervention: No taping (control group)
Number of subjects: 60
Study 26500320 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls Management Exercise programme (FaME)
Number of subjects: 1256
Study 26500320 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (OEP)
Number of subjects: 1256
Study 26500320 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1256
Study 26500320 — intervention group
Group type: EXPERIMENTAL
Intervention: FaME
Number of subjects: 1256
Study 26500320 — intervention group
Group type: EXPERIMENTAL
Intervention: FaME and OEP
Number of subjects: 1256
Study 23254223 — intervention group
Group type: COMPARATOR
Intervention: $10 pre-incentive only
Number of subjects: 3000
Study 23254223 — intervention group
Group type: EXPERIMENTAL
Intervention: $2 pre-incentive and $10 promised incentive
Number of subjects: 3000
Study 21605278 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodopovidone (20mL of a 10% solution)
Number of subjects: 73
Study 21605278 — intervention group
Group type: COMPARATOR
Intervention: Cosmetic talc (5g)
Number of subjects: 73
Study 21605278 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodopovidone and Cosmetic talc
Number of subjects: 73
Study 16570572 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency endoscopic variceal ligation
Number of subjects: 125
Study 16570572 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin (250 microg bolus plus infusion at 250 microg/hour for 48 hours)
Number of subjects: 125
Study 16570572 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin
Number of subjects: 125
Study 12642266 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic fixation group (bone plug grafted into tibial tunnel)
Number of subjects: 60
Study 12642266 — intervention group
Group type: COMPARATOR
Intervention: Nonanatomic fixation group (traditional single-incision reconstruction)
Number of subjects: 60
Study 12642266 — intervention group
Group type: EXPERIMENTAL
Intervention: All-inside anatomic fixation group
Number of subjects: 60
Study 11319710 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofu meal
Number of subjects: 15
Study 11319710 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean meat meal
Number of subjects: 15
Study 11319710 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat meal with added animal fat
Number of subjects: 15
Study 11319710 — intervention group
Group type: EXPERIMENTAL
Intervention: High animal fat meal
Number of subjects: 15
Study 9509965 — intervention group
Group type: EXPERIMENTAL
Intervention: i.o. + i.v. (n = 10)
Number of subjects: 38
Study 9509965 — intervention group
Group type: EXPERIMENTAL
Intervention: i.o. (n = 8)
Number of subjects: 38
Study 9509965 — intervention group
Group type: COMPARATOR
Intervention: i.v. (n = 20)
Number of subjects: 38
Study 9509965 — intervention group
Group type: EXPERIMENTAL
Intervention: i.o.
Number of subjects: 38
Study 9509965 — intervention group
Group type: COMPARATOR
Intervention: i.v.
Number of subjects: 38
Study 9509965 — intervention group
Group type: EXPERIMENTAL
Intervention: i.o. + i.v., i.o., i.v.
Number of subjects: 38
Study 9509965 — intervention group
Group type: EXPERIMENTAL
Intervention: i.o. and i.v.
Number of subjects: 38
Study 7914470 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 mg/m2 administered as a single dose over 1 hour
Number of subjects: 56
Study 7914470 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 mg/m2 administered in divided daily doses for 3 days, each over 1 hour
Number of subjects: 56
Study 3174314 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin (n = 99)
Number of subjects: 199
Study 3174314 — intervention group
Group type: COMPARATOR
Intervention: Saline-vehicle placebo (n = 100)
Number of subjects: 199
Study 30063273 — intervention group
Group type: EXPERIMENTAL
Intervention: Few LDWs
Number of subjects: 132
Study 30063273 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate LDWs
Number of subjects: 132
Study 30063273 — intervention group
Group type: EXPERIMENTAL
Intervention: Many LDWs
Number of subjects: 132
Study 30063273 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk gamblers
Number of subjects: 132
Study 27506677 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Aphasia Therapy (CIAT) for 3 hours per day (10 workdays, total 30 hours)
Number of subjects: 60
Study 27506677 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional communication treatment with same intensity without constraints
Number of subjects: 60
Study 27506677 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy twice a day plus group therapy (total 14 hours)
Number of subjects: 60
Study 25976708 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-setting polyvinyl siloxane (PVS) impression material with heavy body/light body (HB/LB) combination (Imprint 4; 3M ESPE)
Number of subjects: 20
Study 25976708 — intervention group
Group type: COMPARATOR
Intervention: Conventional PVS impression material with HB/LB combination (Imprint 3; 3M ESPE)
Number of subjects: 20
Study 23835684 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 68
Study 21791325 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (transfuse when hematocrit <30% to maintain 30% to 33%)
Number of subjects: 45
Study 21791325 — intervention group
Group type: COMPARATOR
Intervention: Conservative transfusion strategy (transfuse when hematocrit <24% to maintain 24% to 27%)
Number of subjects: 45
Study 21791325 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 45
Study 21791325 — intervention group
Group type: COMPARATOR
Intervention: Conservative transfusion strategy
Number of subjects: 45
Study 19453318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided nerve block
Number of subjects: 44
Study 19453318 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation
Number of subjects: 44
Study 16682573 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim telephone model (IT)
Number of subjects: 192
Study 16682573 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation management service (AMS)
Number of subjects: 192
Study 14731059 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine (Nipolept) [12.5-150 mg/day]
Number of subjects: 24
Study 11736772 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion (0-300 microg x kg(‐1) x min(‐1))
Number of subjects: 68
Study 11736772 — intervention group
Group type: COMPARATOR
Intervention: Control group (no esmolol infusion)
Number of subjects: 68
Study 11736772 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 11736772 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 68
Study 9496288 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded RCTs
Number of subjects: 0
Study 9496288 — intervention group
Group type: COMPARATOR
Intervention: Standard RCTs
Number of subjects: 0
Study 8498768 — intervention group
Group type: EXPERIMENTAL
Intervention: History of blood transfusion
Number of subjects: 37337
Study 8498768 — intervention group
Group type: COMPARATOR
Intervention: No blood transfusion
Number of subjects: 37337
Study 31255988 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented training at 100% intensity (n=7)
Number of subjects: 20
Study 31255988 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented training at 50% intensity (n=8)
Number of subjects: 20
Study 31255988 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy (n=5)
Number of subjects: 20
Study 29465201 — intervention group
Group type: EXPERIMENTAL
Intervention: esCCO (Estimated continuous cardiac output)
Number of subjects: 23
Study 29465201 — intervention group
Group type: EXPERIMENTAL
Intervention: esCCO
Number of subjects: 23
Study 26817175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate 20 mg/day
Number of subjects: 68
Study 26817175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate plus Folate 5 mg/day
Number of subjects: 68
Study 26817175 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate 5 mg/day
Number of subjects: 68
Study 26817175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate
Number of subjects: 68
Study 26817175 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 68
Study 23398530 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg
Number of subjects: 408
Study 23398530 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 408
Study 23398530 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 408
Study 23398530 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (all doses)
Number of subjects: 408
Study 23398530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 23398530 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 408
Study 21470815 — intervention group
Group type: COMPARATOR
Intervention: CoCr‐EES
Number of subjects: 1530
Study 21470815 — intervention group
Group type: EXPERIMENTAL
Intervention: PtCr‐EES
Number of subjects: 1530
Study 18975504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular placentrex injection along with two-week conventional therapy
Number of subjects: 100
Study 18975504 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 100
Study 16311297 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI patients
Number of subjects: 2055
Study 16311297 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2055
Study 12846709 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 0.35 mg.kg‐1
Number of subjects: 118
Study 12846709 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg
Number of subjects: 118
Study 12846709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 11151878 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg i.v. azathioprine over 36 h
Number of subjects: 9
Study 11151878 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg i.v. azathioprine over 36 h
Number of subjects: 9
Study 11151878 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg i.v. azathioprine as three 8‐h infusions over 3 days
Number of subjects: 9
Study 9120123 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CVVHD blood lines and heparin concentration (100 units/ml)
Number of subjects: 26
Study 9120123 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified circuit design with heparin delivered in a more dilute volume (10 units/ml)
Number of subjects: 26
Study 9120123 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both circuit configurations
Number of subjects: 26
Study 9120123 — intervention group
Group type: COMPARATOR
Intervention: Pre-heparin APTT
Number of subjects: 26
Study 1732434 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (15-minute structured protocol addressing educational, psychosocial, and practical barriers)
Number of subjects: 90
Study 1732434 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 90
Study 1732434 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no telephone counseling)
Number of subjects: 90
Study 6326927 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluid intake (greater than or equal to 3 1/24 h) with chemotherapeutic regimens
Number of subjects: 80
Study 6326927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate to render urine neutral
Number of subjects: 80
Study 6326927 — intervention group
Group type: COMPARATOR
Intervention: No sodium bicarbonate supplement
Number of subjects: 80
Study 6326927 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluid intake
Number of subjects: 80
Study 6326927 — intervention group
Group type: EXPERIMENTAL
Intervention: Light chain proteinuria
Number of subjects: 80
Study 31674317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 31674317 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 30144796 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 409
Study 30144796 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil patient controlled analgesia (PCA)
Number of subjects: 409
Study 30144796 — intervention group
Group type: COMPARATOR
Intervention: No pharmacological pain relief
Number of subjects: 409
Study 30144796 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of childbirth antepartum
Number of subjects: 409
Study 27497386 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 80
Study 27497386 — intervention group
Group type: COMPARATOR
Intervention: Adenoid hypertrophy group
Number of subjects: 80
Study 24310049 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription opioid analgesics (oral)
Number of subjects: 11
Study 22701017 — intervention group
Group type: EXPERIMENTAL
Intervention: TPTD 20 μg once daily by sc injection
Number of subjects: 58
Study 22701017 — intervention group
Group type: COMPARATOR
Intervention: ZOL 5 mg by iv infusion
Number of subjects: 58
Study 20163073 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK using the SCHWIND AMARIS excimer laser
Number of subjects: 358
Study 17959576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care services (usual care plus standardized services from a clinical pharmacist, including an initial comprehensive in-home medication assessment and two follow-up visits)
Number of subjects: 154
Study 17959576 — intervention group
Group type: COMPARATOR
Intervention: Usual care (services typically provided by the visiting nurses association)
Number of subjects: 154
Study 15173680 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening
Number of subjects: 0
Study 15463834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin nebuliser solution (TNS) 300 mg by aerosol twice daily (b.i.d.)
Number of subjects: 396
Study 15463834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study 9828870 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathy treatment for warts
Number of subjects: 60
Study 9828870 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for warts
Number of subjects: 60
Study 9828870 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures during waxing moon
Number of subjects: 60
Study 9828870 — intervention group
Group type: COMPARATOR
Intervention: Surgical procedures during waning moon
Number of subjects: 60
Study 10142083 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Case Management System/Community Based Care Coordination Project
Number of subjects: 0
Study 10142083 — intervention group
Group type: EXPERIMENTAL
Intervention: Care coordination
Number of subjects: 0
Study 2483572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg once daily)
Number of subjects: 30
Study 2483572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg twice daily)
Number of subjects: 30
Study 1053442 — intervention group
Group type: EXPERIMENTAL
Intervention: RAST (Phadebas)
Number of subjects: 141
Study 1053442 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick test
Number of subjects: 141